Postsurgical treatment with pembrolizumab doubles cancer-free time for bladder cancer patients
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...
EurekAlert!5d
Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer
Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...
Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...
icr.ac.uk10mon
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer
do not provide enough evidence that the drug would offer a larger benefit than the current, ‘extreme’ form of chemotherapy. It has asked the manufacturer of pembrolizumab, Merck & Co., Inc., who ...
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Yahoo Finance1d
Merck & Co., Inc. (MRK)
aggressive cancer that forms in the lining of RAHWAY, N.J., September 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...
pharmaphorum12d
WCLC: Summit trumpets data with Keytruda challenger
MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a ...
Promising BNT327 Data Bolsters BioNTech’s Buy Rating, With a Target of $171
Analyst John Newman of Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), retaining the price target of ...
First Cancer Medicine Decision Following Pharmac Funding Boost
Pharmac’s Director of Pharmaceuticals, Geraldine MacGibbon, says Pharmac is really pleased to announce our first decision for cancer medicines since the Government provided additional funding in June ...
Targeted Oncology13d
The Targeted Pulse: IL-21 Promises to Revolutionize Treatment for Glioblastoma, Pembrolizumab Trials Halted in Lung and Skin Cancer, and More
IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Yahoo Finance6d
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Based on the results from KEYNOTE-006 in December 2015, the U.S. Food and Drug Administration approved KEYTRUDA for ...